149 related articles for article (PubMed ID: 28760097)
1. Adherence to Antipsychotic Therapy: Association With Hospitalization and Medicare Spending Among Part D Enrollees With Schizophrenia.
Roberto P; Brandt N; Onukwugha E; Perfetto E; Powers C; Stuart B
Psychiatr Serv; 2017 Nov; 68(11):1185-1188. PubMed ID: 28760097
[TBL] [Abstract][Full Text] [Related]
2. Adverse clinical events among medicare beneficiaries using antipsychotic drugs: linking health insurance benefits and clinical needs.
Fung V; Price M; Busch AB; Landrum MB; Fireman B; Nierenberg A; Dow WH; Hui R; Frank R; Newhouse JP; Hsu J
Med Care; 2013 Jul; 51(7):614-21. PubMed ID: 23752219
[TBL] [Abstract][Full Text] [Related]
3. Rates and predictors of antipsychotic non-adherence and hospitalization in Medicaid and commercially-insured patients with schizophrenia.
Lang K; Federico V; Muser E; Menzin J; Menzin J
J Med Econ; 2013 Aug; 16(8):997-1006. PubMed ID: 23777223
[TBL] [Abstract][Full Text] [Related]
4. Association of chronic obstructive pulmonary disease maintenance medication adherence with all-cause hospitalization and spending in a Medicare population.
Simoni-Wastila L; Wei YJ; Qian J; Zuckerman IH; Stuart B; Shaffer T; Dalal AA; Bryant-Comstock L
Am J Geriatr Pharmacother; 2012 Jun; 10(3):201-10. PubMed ID: 22521808
[TBL] [Abstract][Full Text] [Related]
5. Adherence to antipsychotics and cardiometabolic medication: association with health care utilization and costs.
Hansen RA; Maciejewski M; Yu-Isenberg K; Farley JF
Psychiatr Serv; 2012 Sep; 63(9):920-8. PubMed ID: 22706887
[TBL] [Abstract][Full Text] [Related]
6. Estimating the Impact of Adherence to and Persistence with Atypical Antipsychotic Therapy on Health Care Costs and Risk of Hospitalization.
Jiang Y; Ni W
Pharmacotherapy; 2015 Sep; 35(9):813-22. PubMed ID: 26406773
[TBL] [Abstract][Full Text] [Related]
7. Antiparkinson drug adherence and its association with health care utilization and economic outcomes in a Medicare Part D population.
Wei YJ; Palumbo FB; Simoni-Wastila L; Shulman LM; Stuart B; Beardsley R; Brown CH
Value Health; 2014 Mar; 17(2):196-204. PubMed ID: 24636377
[TBL] [Abstract][Full Text] [Related]
8. Adherence and economic impact of paliperidone palmitate versus oral atypical antipsychotics in a Medicare population.
Joshi K; Muser E; Xu Y; Schwab P; Datar M; Suehs B
J Comp Eff Res; 2018 Aug; 7(8):723-735. PubMed ID: 29722547
[No Abstract] [Full Text] [Related]
9. The association between class of antipsychotic and rates of hospitalization: results of a retrospective analysis of data from the 2005 Medicare current beneficiary survey.
Kennedy J; Tien YY; Cohen LJ; Sclar DA; Liu D; Blodgett EG; Engle J
Clin Ther; 2009 Dec; 31(12):2931-9. PubMed ID: 20110033
[TBL] [Abstract][Full Text] [Related]
10. Antipsychotic Medication Adherence and Diabetes-Related Hospitalizations Among Medicaid Recipients With Diabetes and Schizophrenia.
Egglefield K; Cogan L; Leckman-Westin E; Finnerty M
Psychiatr Serv; 2020 Mar; 71(3):236-242. PubMed ID: 31744428
[TBL] [Abstract][Full Text] [Related]
11. How Much Does Medication Nonadherence Cost the Medicare Fee-for-Service Program?
Lloyd JT; Maresh S; Powers CA; Shrank WH; Alley DE
Med Care; 2019 Mar; 57(3):218-224. PubMed ID: 30676355
[TBL] [Abstract][Full Text] [Related]
12. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia.
Gilmer TP; Dolder CR; Lacro JP; Folsom DP; Lindamer L; Garcia P; Jeste DV
Am J Psychiatry; 2004 Apr; 161(4):692-9. PubMed ID: 15056516
[TBL] [Abstract][Full Text] [Related]
13. Regional Variation in Physician Adoption of Antipsychotics: Impact on US Medicare Expenditures.
Donohue JM; Normand SL; Horvitz-Lennon M; Men A; Berndt ER; Huskamp HA
J Ment Health Policy Econ; 2016 Jun; 19(2):69-78. PubMed ID: 27453458
[TBL] [Abstract][Full Text] [Related]
14. Atypical antipsychotic adherence is associated with lower inpatient utilization and cost in bipolar I disorder.
Broder MS; Greene M; Chang E; Hartry A; Yan T; Yermilov I
J Med Econ; 2019 Jan; 22(1):63-70. PubMed ID: 30376745
[TBL] [Abstract][Full Text] [Related]
15. The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia.
Chen H; Kennedy WK; Dorfman JH; Fincham JE; Reeves J; Martin BC
Curr Med Res Opin; 2007 Jun; 23(6):1351-65. PubMed ID: 17559734
[TBL] [Abstract][Full Text] [Related]
16. One-Year Medication Treatment Patterns, Healthcare Resource Utilization, and Expenditures for Medicaid Patients with Schizophrenia Starting Oral Atypical Antipsychotic Medication.
Richards K; Johnsrud M; Zacker C; Sasané R
Adm Policy Ment Health; 2024 Mar; 51(2):207-216. PubMed ID: 38071724
[TBL] [Abstract][Full Text] [Related]
17. Medication Adherence Based on Part D Claims for Patients With Heart Failure After Hospitalization (from the Atherosclerosis Risk in Communities Study).
Sueta CA; Rodgers JE; Chang PP; Zhou L; Thudium EM; Kucharska-Newton AM; Stearns SC
Am J Cardiol; 2015 Aug; 116(3):413-9. PubMed ID: 26026867
[TBL] [Abstract][Full Text] [Related]
18. Association between second-generation antipsychotic medication half-life and hospitalization in the community treatment of adult schizophrenia.
Broder MS; Bates JA; Jing Y; Hebden T; Forbes RA; Chang E
J Med Econ; 2012; 15(1):105-11. PubMed ID: 21991926
[TBL] [Abstract][Full Text] [Related]
19. Antiparkinson drug use and adherence in medicare part D beneficiaries with Parkinson's disease.
Wei YJ; Palumbo FB; Simoni-Wastila L; Shulman LM; Stuart B; Beardsley R; Brown C
Clin Ther; 2013 Oct; 35(10):1513-1525.e1. PubMed ID: 24139423
[TBL] [Abstract][Full Text] [Related]
20. Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia.
Offord S; Lin J; Mirski D; Wong B
Adv Ther; 2013 Mar; 30(3):286-97. PubMed ID: 23483449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
